Clinical Scalp Care Gains Ground as Dandruff Is Linked to Hair Loss

Analysis

Scalp health moved firmly into the clinical column this fortnight, with WWD asking whether clinical hair care is having its moment as dandruff and hair loss products drive shampoo and treatment innovation ^[1]. The framing matters for UK retail buyers: what was a wash-day category is increasingly merchandised alongside diagnosis-led skincare. Reinforcing that shift, dermatologists told Women's Health that treating dandruff — described as a common scalp condition — could help reduce hair loss, a claim that gives brands a defensible bridge between anti-flake and density benefits ^[2]. The Telegraph pushed the same argument further upstream for UK readers, setting out how to keep the scalp microbiome healthy in service of strong, shiny hair ^[3].

Consumer-facing product discovery remains dominated by growth serums and topical treatments. Good Housekeeping UK published a round-up of the best hair growth serums for fuller, healthier-looking hair ^[4], while Byrdie ran eleven tested hair loss treatments, reporting fuller hair, less shedding and new growth among its testers ^[5]. Interest in alternatives to the established topical standard is also building, with Vogue Arabia surveying topical minoxidil alternatives to boost hair growth ^[6], and health.com examining whether castor oil deserves its reputation, listing five benefits ^[7].

Investment activity suggests the pipeline behind these claims is thickening. Lilly-backed Absci raised $100m to progress its endometriosis and hair loss therapy programmes ^[8], and Mallia secured €3m to expand its hormone-free hair loss products ^[9]. Meanwhile, commentary in Premier Woman Alive noted scientists' suggestions that hair loss could soon be reversed, reflecting how far the reversal narrative has travelled beyond trade press ^[10].